This project is an open, single-center, prospective study aimed at developing high-sensitivity, high-specificity enrichment SERS chips using femtosecond laser processing technology. It involves extracting information from blood samples of ovarian cancer patients and normal controls, specifically identifying cancer and non-cancer signals. The study will construct a statistical algorithm model for the early diagnosis of ovarian cancer, enabling early identification and intervention for ovarian cancer patients.
The subjects understand the trial process, sign the informed consent form, voluntarily participate in the study, and are capable of following the protocol;
Severe or uncontrolled diseases, including but not limited to: uncontrollable nausea and vomiting, gastrointestinal diseases that may interfere with drug absorption and metabolism, mental illnesses affecting the patient's ability to sign the informed consent form, a history of severe cardiovascular disease, infectious diseases (such as syphilis, AIDS, active hepatitis C, or active hepatitis B), infectious conditions (such as abscesses), or active rheumatic diseases, etc.;
A history of blood transfusion within 4 weeks prior to the study;
Pregnant, postpartum, or breastfeeding patients, or patients planning to become pregnant during the study treatment;
Patients with a history of other tumors;
The subjects include patients with epithelial ovarian cancer, while the control group consists of patients undergoing surgery for benign diseases.
Case-control
Prospective
No intervention
Other interventionNo intervention
PFS PFS
progression free survival
OS
OS (overall survival) is defined as the time which begins at diagnosis and up to the time of death
Click on the lead sponsor to view all of their trials.
